Suppr超能文献

唐氏综合征成人队列中低骨转换和低骨密度。

Low bone turnover and low bone density in a cohort of adults with Down syndrome.

机构信息

Department of Family Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR 72205, USA.

出版信息

Osteoporos Int. 2013 Apr;24(4):1333-8. doi: 10.1007/s00198-012-2109-4. Epub 2012 Aug 18.

Abstract

UNLABELLED

Increased incidence of osteoporosis in Down syndrome has been reported, but etiology is not established. We report low bone turnover markers and bone mineral density (BMD) in a cohort of people with Down syndrome without consistent clinical risk factors. Our results should guide future studies and treatments for this common problem.

INTRODUCTION

To better understand the etiology for osteoporosis in Down syndrome (DS), we measured bone density by dual-energy X-ray absorptiometry (DXA) and circulating biochemical markers of bone formation and resorption in a cohort of 30 community-dwelling DS adults.

METHODS

Seventeen males and 13 females followed in the University of Arkansas Down Syndrome Clinic were evaluated by DXA to estimate BMD and underwent phlebotomy to measure serum procollagen type-1 intact N-terminal propeptide (P1NP) to evaluate bone formation, and serum C-terminal peptide of type-I collagen (CTx) to evaluate bone resorption.

RESULTS

Seven of 13 DS females and 12 of 17 DS males had low bone mass at one of measured sites (z≤-2.0). When data were grouped by age, males had apparent osteopenia earlier than females. The mean P1NP in the normal group was 19.2±5.2 ng/ml vs. 2.2±0.9 ng/ml in the DS group (P=0.002). Serum CTx levels in the normal group were 0.4±0.1 ng/ml vs. 0.3±0.1 ng/ml (P=0.369).

CONCLUSIONS

Low BMD in adults with DS is correlated with a significant decrease in bone formation markers, compared to controls without DS, and is independent of gender. These data suggest that diminished osteoblastic bone formation and inadequate accrual of bone mass, with no significant differences in bone resorption, are responsible for the low bone mass in DS. These observations question the use of antiresorptive therapy in this population and focus attention on increasing bone mass by other interventions.

摘要

目的

为了更好地了解唐氏综合征(DS)患者骨质疏松症的病因,我们通过双能 X 射线吸收法(DXA)测量了一群居住在社区的 DS 成年患者的骨密度,并检测了循环骨形成和骨吸收的生化标志物。

方法

我们评估了在阿肯色大学唐氏综合征诊所随访的 30 名 DS 成人患者的 DXA,以估计骨密度,并进行了静脉采血以测量血清Ⅰ型前胶原氨基端肽(P1NP)以评估骨形成,以及血清Ⅰ型胶原 C 端肽(CTX)以评估骨吸收。

结果

13 名 DS 女性中有 7 名和 17 名 DS 男性中有 12 名在一个测量部位的骨密度较低(z≤-2.0)。当按年龄分组时,男性比女性更早出现骨质疏松症。正常组的平均 P1NP 为 19.2±5.2ng/ml,DS 组为 2.2±0.9ng/ml(P=0.002)。正常组的血清 CTx 水平为 0.4±0.1ng/ml,DS 组为 0.3±0.1ng/ml(P=0.369)。

结论

与无 DS 的对照组相比,DS 成人的低骨密度与骨形成标志物显著降低相关,且与性别无关。这些数据表明,破骨细胞骨形成减少和骨量积累不足导致了 DS 中的低骨量,而骨吸收无显著差异。这些观察结果质疑了在该人群中使用抗吸收治疗的方法,并将注意力集中在通过其他干预措施增加骨量上。

相似文献

1
Low bone turnover and low bone density in a cohort of adults with Down syndrome.
Osteoporos Int. 2013 Apr;24(4):1333-8. doi: 10.1007/s00198-012-2109-4. Epub 2012 Aug 18.
2
Bone mineral density in adults with Down syndrome.
Osteoporos Int. 2017 Oct;28(10):2929-2934. doi: 10.1007/s00198-017-4133-x. Epub 2017 Jul 6.
3
Contribution of bone turnover markers to the variation in bone mineral density: a study in Vietnamese men and women.
Osteoporos Int. 2018 Dec;29(12):2739-2744. doi: 10.1007/s00198-018-4700-9. Epub 2018 Sep 8.
7
The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland.
Osteoporos Int. 2024 Sep;35(9):1605-1613. doi: 10.1007/s00198-024-07155-9. Epub 2024 Jun 26.
8
The levels of bone turnover markers in Chinese postmenopausal women: Peking Vertebral Fracture study.
Menopause. 2011 Nov;18(11):1237-43. doi: 10.1097/gme.0b013e31821d7ff7.
10
Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison's disease.
Endocrine. 2024 May;84(2):711-719. doi: 10.1007/s12020-024-03709-3. Epub 2024 Feb 9.

引用本文的文献

1
Male Down syndrome Ts65Dn mice have impaired bone regeneration.
Bone. 2025 Mar;192:117374. doi: 10.1016/j.bone.2024.117374. Epub 2024 Dec 13.
2
Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model.
Dis Model Mech. 2024 Sep 1;17(9). doi: 10.1242/dmm.050914. Epub 2024 Sep 23.
4
Endocrine, auxological and metabolic profile in children and adolescents with Down syndrome: from infancy to the first steps into adult life.
Front Endocrinol (Lausanne). 2024 Apr 8;15:1348397. doi: 10.3389/fendo.2024.1348397. eCollection 2024.
5
Compromised femoral and lumbovertebral bone in the Dp(16)1Yey Down syndrome mouse model.
Bone. 2024 Apr;181:117046. doi: 10.1016/j.bone.2024.117046. Epub 2024 Feb 7.
6
The aetiology of atypical bone health in individuals with Down syndrome.
Arch Osteoporos. 2023 Nov 24;18(1):140. doi: 10.1007/s11657-023-01348-1.
7
Atlantoaxial Subluxation in a 10-Year-Old Girl With Down Syndrome: A Case Report.
Cureus. 2023 Aug 23;15(8):e43955. doi: 10.7759/cureus.43955. eCollection 2023 Aug.
10
Low bone mass and impaired fracture healing in mouse models of Trisomy21 (Down syndrome).
Bone. 2022 Sep;162:116471. doi: 10.1016/j.bone.2022.116471. Epub 2022 Jun 15.

本文引用的文献

1
Update on Wnt signaling in bone cell biology and bone disease.
Gene. 2012 Jan 15;492(1):1-18. doi: 10.1016/j.gene.2011.10.044. Epub 2011 Nov 3.
2
Health supervision for children with Down syndrome.
Pediatrics. 2011 Aug;128(2):393-406. doi: 10.1542/peds.2011-1605. Epub 2011 Jul 25.
4
Effects of combined aerobic and resistance exercise training in adults with and without Down syndrome.
Arch Phys Med Rehabil. 2011 Jan;92(1):37-45. doi: 10.1016/j.apmr.2010.09.015.
5
Effect of strength and balance training in children with Down's syndrome: a randomized controlled trial.
Clin Rehabil. 2011 May;25(5):425-32. doi: 10.1177/0269215510382929. Epub 2010 Nov 8.
6
Bone mass in male and female children and adolescents with Down syndrome.
Osteoporos Int. 2011 Jul;22(7):2151-7. doi: 10.1007/s00198-010-1443-7. Epub 2010 Oct 22.
7
Disruption of bone development and homeostasis by trisomy in Ts65Dn Down syndrome mice.
Bone. 2011 Feb;48(2):275-80. doi: 10.1016/j.bone.2010.09.028. Epub 2010 Sep 24.
8
Sclerostin: current knowledge and future perspectives.
Calcif Tissue Int. 2010 Aug;87(2):99-107. doi: 10.1007/s00223-010-9372-1. Epub 2010 May 15.
9
Low adherence to national guidelines for thyroid screening in Down syndrome.
Genet Med. 2009 Jul;11(7):548-51. doi: 10.1097/GIM.0b013e3181a9c250.
10
Endocrine and musculoskeletal abnormalities in patients with Down syndrome.
Nat Rev Endocrinol. 2009 Jun;5(6):327-34. doi: 10.1038/nrendo.2009.80.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验